Trial Profile
A single-centre, randomised, double-blind, placebo-controlled, phase I trial investigating the safety and tolerability of single ascending doses of ALKS-7119 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs ALKS 7119 (Primary)
- Indications Agitation
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Alkermes plc
- 10 Jan 2022 Status changed from recruiting to completed as per results published in the British Journal of Clinical Pharmacology
- 10 Jan 2022 Results published in the British Journal of Clinical Pharmacology
- 28 Apr 2016 Full results from this study, including unblinded safety data, are expected in the second half of 2016, according to an Alkermes media release.